Iksuda Therapeutics – Forging stable relationships for antibody-drug conjugates.
Iksuda Therapeutics are featured in this month’s Nature magazine, a Q&A with their Chief
Sanj Kumar joins Atelerix as Chief Business Officer
Atelerix, pioneers in the storage and transport of cells at room temperature, announced today
Newcastle delegation showcase our smart city to the world
Invest Newcastle is attending the Smart City Expo World Congress to showcase our city
Biosphere Tenants nominated for 2019 Bionow awards.
Three of the Biosphere tenants have been shortlisted for the 2019 Bionow Awards. Iksuda Therapeutics,
Biosphere company do their bit for charity.
This Movember, the team at Iksuda are raising funds for men's health. We’ll be running,
Newcastle Helix win prestigious real estate award
The Team at Newcastle Helix are celebrating after winning the ‘Collaborators Award’ in the EG
Q&A: Iksuda Therapeutics: Leading the way on helping to advance care for ovarian and lung cancer patients
We talk to David Simpson, CEO at Iksuda Therapeutics about what they do, how
Taking Newcastle to the world at BioJapan 2019
Invest Newcastle recently attended BioJapan as part of a UK delegation led by MedCity
Biosphere tenant Iksuda Therapeutics presents first data on lead antibody drug conjugate, demonstrating effective tumour regression.
Iksuda Therapeutics (Iksuda), a developer of next generation Antibody Drug Conjugates (ADCs), today announced
Transformational cell technology helping to improve lives across the world
Atelerix is a spin out from Newcastle University and pioneers in the storage and